Ruti Aga's Six Years: How a Forged Prescription Turned a Two-Year Absence Into Career Death

Ruti Aga's name was, for me, a benchmark that lived on a scoreboard one day and in a spreadsheet column the next. The winner of the 2026 Tokyo Marathon, three second-place finishes at World Marathon Majors — those numbers are, by themselves, the entire ledger of a career. But when the news broke that she had received a six-year ban, the first question in front of me was not what she had done. It was: how does six get built?

Six is not a round number. It is a sum. And under anti-doping rules, no sanction is spontaneously six years long; it is always the addition of two separate violations. The day I broke that sum apart, I understood that this story is not about a marathon. It is about a piece of paper.

Context: The story the scoreboard never showed

Aga comes from that generation of Ethiopian women's marathon running in which a personal best of two hours eighteen minutes does not automatically earn selection to the national team. That context matters, because later we will see that her removal does not move Ethiopia's medal capacity by a single inch — and that is the most brutal truth in this entire case.

The part of her record that is public is clean: the 2026 Tokyo Marathon title, and the three World Marathon Majors silver medals. This is a commercial-tier but genuinely world-class marathon career. She is 32. On the marathon age curve, that sits exactly at the point where the peak has passed and the decline has begun.

Now the event that started everything. In March, at a half marathon in China — which she won — a sample showed a prohibited substance. Here I have to record something that is missing from virtually every report being written about this story: the time of that race, the splits, the field strength — none of it is on record anywhere. I cannot comment on a mark that does not exist. A performance with no number is not a performance; it is a fact — she won, and testing was present. That is all.

The Athletics Integrity Unit (AIU) statement is the only primary source in this story. Everything else — the age, the titles, the injury, the prescription — are secondary details that I am weighing on separate scales.

Core: Not the substance, the route; not the route, the prescription

This is where the part I wrote this piece for begins.

The first shock: the misclassification of the substance

In the report that carried this news, methylprednisolone was called a "prohibited steroid" and it was claimed that WADA classes it as "performance enhancing." This is technically wrong, and this error breaks the entire legal understanding of the case.

Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (class S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral, or rectal routes. A therapeutic knee injection given out-of-competition is entirely legal. It becomes a violation only if residues are present in-competition.

Which means the whole case hinges not on the drug but on route and timing. And that is precisely where a legitimate defence pathway existed — timing, route, and medical necessity.

I want to stop here and say something I learned years ago. In April 2026, my right hamstring tore in the heats of the Karnataka State Meet, and after that I watched my coach's hand-timed 58.9 seconds become a FAT-verified 60.4 on the official sheet. I quit the track that August and rebuilt three seasons of my own training logs into a spreadsheet to find out exactly where the numbers had lied to me. I trusted the stopwatch until the day it lied to my face. After that day I do not accept any number without a source — and in this news story, the substance class is written wrong. It is the same kind of error: a number that turned the direction of an entire story, without anyone challenging it.

The second shock: not the substance, the prescription

Aga cited a knee injury — and I want to say immediately that this is mechanically entirely plausible. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. That plausibility is exactly why the prescription becomes the decisive fact in this case. A genuine, documented treatment is defended with real records. Not with a forged prescription.

According to the AIU statement, the "doctor" who wrote the prescription was a family member of Aga's, with no medical registration, who claimed he had used "an old prescription pad from a former workplace." The clinic named on the prescription did not exist — and it explicitly denied ever having such a pad.

Three independent verification failures, in one prescription.

First: the clinic did not exist. Second: the "doctor" was unregistered, and he was family. Third: the pad was disowned by the clinic itself. These are not three separate doors that one story can pass through — they are three separate walls.

And here is what is least said in the reporting: the four-year tampering sanction comes from an interview, not from a document alone. That is, the sanction was built from statements made under questioning. Language and translation conditions in AIU interviews with Ethiopian athletes are a recurring point of contention — and I am recording this so that it is not ignored in any future case. This is not an excuse. It is a procedural variable.

The third shock: the arithmetic of six

Now the sum I wrote all this for.

Two years for the presence violation. Four years for tampering. Six total. This structure is standard, not exceptional.

The two-year figure tells us the panel found the substance to be a "Specified Substance," without proven intent — that is the category where the sanction sits at two years. And four years is the Code's standard sanction for tampering.

But the real information is not in the sum, it is behind the sum. This arithmetic tells us the panel rejected the "no significant fault" mitigation — the mitigation that could otherwise have reduced the presence sanction. And it was rejected because the forged prescription is itself circumstantial evidence of concealment intent.

There is a paradox here I cannot leave unrecorded: forged documentation is evidence of concealment intent, yet it did not escalate the presence sanction — it went into a separate, four-year charge. The panel kept the two violations cleanly separate, which is procedurally correct, but creates an odd picture: two years for the drug, and double that for trying to hide the drug.

The fourth shock: something that looks like relief, and is not

The statement also says the ban runs from 10 September, and that the athlete had been on provisional suspension since 10 September itself. At first glance it looks as if the date was backdated, meaning some relief was granted.

This is not relief. This is accounting. Time on provisional suspension counts against the ban — the athlete gains nothing in real terms; her sanction is simply counted from the day she was already out. It is a procedural benefit, not a reduction.

Add a six-year ban at age 32. Return age: roughly 38. In the depth of Ethiopian women's marathon running, a 38-year-old with a doping mark on her record will, in practice, never be selected. On paper this is a six-year ban; in practice it is a lifetime one.

The fifth shock: the knee is the real cause, governance is the real root

I am not placing the injury here as an excuse. I am placing it as a causal point.

Chronic knee pathology is a known, load-bearing failure mode in high-volume marathoners. Injured marathoners have a strong incentive to mask pain — because their income comes from appearance fees, not medals. Glucocorticoids are the cheapest, most available tool for masking that pain. And the medical system around them is informal.

Here I come to my "payroll model." In Indian athletics I read a career not as prize money but as employment — Railways, Services, police and PSU quotas, TOPS funding, Khelo India scholarships, state cash awards. The Ethiopian road-running model is different, but its logic is the same: an athlete runs on one coach, one agent, and very little formal medical support. The agent survives on appearance fees; so does the athlete.

And here is the fact I weigh most heavily: Aga had no credentialed team physician — or had one, and did not use that door. A properly managed athlete either (a) holds or applies for a TUE, or (b) observes the WADA route-specific washout period. Neither happened. Instead, a forged prescription was created.

This is not a filing error. This is the signature of an athlete operating without a credentialed team physician.

And from here the individual case becomes a collective one. Because the same informal medical networks serve many athletes in the same training cluster, the likelihood of more cases with this profile in the pipeline is high. I record this not as a prediction but as a structural observation.

The sixth shock: China's circuit — where the appearance-fee economy and the testing economy collide

That March race was in China. My highest-probability reading: it was a World Athletics Label road race, with a strong women's field and in-competition testing — otherwise no AIU sample would exist.

This tier is technically a "Label road race," but economically it is a highly attractive, low-risk income stratum for East African marathoners — races that fill the gap between Majors, with large appearance fees. The same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. This is not coincidence; it is structure — and it is bigger than any one athlete's morality.

Contrarian angle: why the "steroid" story is wrong, and where the real danger lies

Now the part that is being most misunderstood.

This story is being sold under the label "six years for steroids." That label is false, and damaging too — because it puts a valid issue in the wrong box. Methylprednisolone has no proven benefit for endurance performance. When you see a six-year ban for a drug whose endurance benefit is not even established, the necessary question stops being whether the sanction is harsh. The question becomes whether the sanction is for the drug or for the document. And the statement's arithmetic says it plainly: two years for the drug, four for the document.

That is the real lesson of this case, and it is the opposite of the narrative being sold. The AIU's enforcement frontier has now shifted from "detection" to "document verification." Aga's case is not an outlier but a member of a recognisable family — those East African road-racing cases where an initial substance violation is compounded by a fabricated or altered explanation.

And here is the blind spot nobody is looking at: on one side, questions will be raised about this severity toward African road runners. On the other, the argument holds that if there is structural injustice, it should be visible too — in this testing economy, those runners are tested most who hold the least defence apparatus. I am not deciding which argument wins. I am only saying that to call this case "steroids" and make the question of the sanction disappear — and to call it "six years" and make the question of process disappear — are the same mistake.

One last, unpleasant thing I cannot leave unwritten: this story shows where a genuine therapeutic treatment leads — no case at all, a reprimand or a much-reduced period, and no tampering charge. And where a forged prescription leads — six years. The knee injury ended a season; the prescription ended a career.

Takeaway: next time, watch the prescription, not the scoreboard

Weighing this story, I remembered that 2026 Tokyo final I watched on a desk monitor. That day the scoreboard was telling us everything. Today the scoreboard that exists tells us nothing — no mark from Aga's March race is on record, no splits, no field strength. What survives is a sum: two plus four.

Over the coming months, what I will track is not a timing. It is this: how many more cases with this profile surface — the same cluster, the same shared informal medical network, the same "old prescription pad." If two or three more appear, we will have to conclude the problem is not one athlete's honesty, but the governance gap in which a single knee injection swallows an entire career.

The question is not whether Aga will run again. The question is whether the next Ethiopian runner with a knee injury will find, instead of a forged prescription, the door of a real doctor. Until that answer changes, these six years — two plus four — will be repeated.